Hellesnes R, Kvammen O, Myklebust TA, et al. - Researchers analyzed testicular cancer survivors (TCS) treated in the cisplatin era, to determine second cancer (SC) risk in these individuals in this population-based analysis utilizing complete information on total treatment burden. A total of 5,625 1-year TCS were analyzed. Increased SC risk was observed following surgery only, with site-specific elevated risks of thyroid cancer and melanoma. The risks for cancers of the small intestine, bladder, kidney and lung were found to be increased by 2.0- to 3.7-fold following chemotherapy (CT). Following ≥ 2 cycles of cisplatin-based CT, they observed a 1.6- to 2.1-fold rise in the risk of SC. The risks for cancers of the stomach, small intestine, liver, pancreas, lung, kidney and bladder were found to be increased by 1.5- to 4.4-fold in relation to radiotherapy (RT). Increased risks for hematological malignancies were observed following combined CT and RT. Overall, an increased risk of developing SC was evident in TCS treated in the cisplatin era, especially following treatment with cisplatin-based CT and/or RT.